ClinicalTrials.gg
CompletedNCT02718066Updated Jul 30, 2026Results posted

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

A Phase 1/2 interventional study of HBI-8000 in combination with nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer, sponsored by HUYABIO International, LLC.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by HUYABIO International, LLC. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
44th of 142
96 · median 50
Started
2016
with 15 others
Phase 1/2
17 of 142
6 open now
Registered
33rd of 142
by date

Among the 142 studies testing nivolumab in Melanoma, this one is the 44th largest by enrollment, is one of 16 that started in 2016, is one of 17 in phase 1/2, and was the 33rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC).

The primary objective of this study is:

-To evaluate the safety and tolerability of HBI-8000 when combined with a standard dose and regimen of nivolumab, and to evaluate frequency and severity of toxicities of this combination treatment

The secondary objectives of this study include:

  • To explore the efficacy of study treatment as measured by Objective Response Rate (ORR), Disease Control Rate (DCR), Clinical Benefit Rate (CBR), Duration of Response (DoR), Progression-Free Survival (PFS) in all subjects treated at RP2D
  • To obtain pharmacokinetics of twice weekly HBI-8000 when administered in combination with nivolumab administered once every two weeks (Phase 1b all sites)
  • To obtain pharmacokinetics of twice weekly HBI-8000 when administered in combination with nivolumab administered per package insert dose and administration (Phase 2 selected sites)
  • To characterize the effect of HBI-8000 on the electrocardiogram QT corrected (QTc) interval (Phase 1b only)

Exploratory:

  • To investigate the kinetics and extent of histone acetylation in peripheral blood mononuclear cells (PBMC) at the RP2D of HBI-8000 (Phase 2 only)
  • To explore potential biomarkers for disease response through sequential sampling of blood and/or tumor tissue in subjects consenting to correlative sub-studies at participating sites (Phase 2 only)

Dose Escalation (Phase 1b) will include up to 18 subjects, followed by Cohort Expansion (Phase 2) including up to 100 subjects (melanoma up to 60 subjects and NSCLC up to 40 subjects at MTD and/or RP2D.

Read the detailed description

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC).

The primary objective of this study is:

-To evaluate the safety and tolerability of HBI-8000 when combined with a standard dose and regimen of nivolumab, to determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) and to evaluate frequency and severity of toxicities of this combination treatment

The secondary objectives of this study include:

  • To explore the efficacy of study treatment as measured by Objective Response Rate (ORR), Disease Control Rate (DCR), Clinical Benefit Rate (CBR), Duration of Response (DoR), Progression-Free Survival (PFS) in all subjects treated at RP2D
  • To obtain pharmacokinetics of twice weekly HBI-8000 when administered in combination with nivolumab administered once every two weeks (Phase 1b all sites; Phase 2 selected sites)
  • To characterize the effect of HBI-8000 on the electrocardiogram QT corrected (QTc) interval (Phase 1b only)

Exploratory:

-To investigate the kinetics and extent of histone acetylation in peripheral blood mononuclear cells (PBMC) at the RP2D of HBI-8000 (Phase 2 only)

Dose Escalation (Phase 1b) will include up to 18 subjects, followed by Cohort Expansion (Phase 2) including up to 100 subjects (melanoma up to 60 subjects and NSCLC up to 40 subjects) at MTD and/or RP2D.

HBI-8000 tablets will be administered at 20, 30, 40 mg/dose, orally twice a week until MTD or 40 mg in Phase 2, if MTD is not reached.

Nivolumab: 240 mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.

A treatment cycle consists of 28 days. Treatment continues until disease progression or unacceptable toxicity.

03

Conditions studied

  • Melanoma
  • Renal Cell Carcinoma
  • Non-Small Cell Lung Cancer

Keywords

  • HBI-8000
  • Nivolumab
  • Melanoma
  • Renal Cell Carcinoma
  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were entered in the study only if they met all of the following criteria:

1. Adults at least 18 years of age. 2. (ECOG) performance status ≤1. 3.

  1. Subjects with histopathologically or confirmed diagnosis of non uveal melanoma, RCC, or NSCLC, for whom the use of nivolumab was indicated. NSCLC subjects with EGFR or ALK genomic aberrations in tumor should have disease progression on FDA approved therapy for these aberrations prior to receiving nivolumab. (Phase 1b).
  2. Subjects with histopathologically or cytologically confirmed diagnosis of non uveal melanoma or NSCLC for whom the use of nivolumab is indicated (Phase 2 expansion). With Protocol Amendment 5, subjects with NSCLC were not eligible for enrollment.

c, Non uveal melanoma and NSCLC subjects whose disease progressed after achieving stable disease (SD) for at least 3 months, with partial response (PR) or complete response (CR) as the best response that was documented by imaging studies on previous treatment with a PD L1 inhibitor with proven efficacy (Phase 2 expansion). With Protocol Amendment 5, subjects with NSCLC were not eligible for enrollment.

4. Subject had at least one measurable target lesion as defined by v1.1 (RECIST 1.1). Melanoma subjects participating in the optional correlative substudy had tumor tissue available from a or unresectable site for PD L1 and correlative biomarker analysis.

5. All prior systemic therapy (chemotherapy, mutation targeting therapy, immune checkpoint therapy), or surgical or radiation treatment was completed at least 4 weeks before study drug* administration (2 weeks for palliative radiotherapy, 1 week for minor surgery), pending full recovery from therapy.

6. The following laboratory results within 7 days prior to study drug* administration: Adequate hematopoietic, electrolyte, hepatic, and renal laboratory findings as defined below: white blood cells (WBC) ≥3000/μL, neutrophils ≥1500/μL, ≥100x103/μL, ≥9.0 g/dL independent of transfusion, creatinine ≤1.5 mg/dL, (AST) and alanine aminotransferase (ALT) ≤3 × (ULN), alkaline phosphatase ≤2.5 x ULN (unless bone metastases present), ≤1.5 × ULN (unless known Gilbert's disease, where value must be ≤3 × ULN), and serum albumin ≥3.0 g/dL.

7. ≥12 weeks. 8. A negative serum pregnancy test at baseline for women of .

9. Were willing to abstain from heterosexual activity or practice physical barrier prior to time of study entry to at least 5 months after the last day of treatment.

10. Had the ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria

Subjects who fulfilled any of the following criteria at screening were not eligible for admission into the study:

  1. History of Grade 3 or above reactions to other monoclonal antibodies.
  2. Subjects with a history of a cardiovascular illness including: congestive heart failure ( Grade III or IV); unstable angina or myocardial infarction within the previous 6 months; or symptomatic cardiac arrhythmia despite medical management. In addition, for Phase 1b only: (Fridericia's correction) (QTcF) >450 ms in male, and >470 ms in female, congenital long QT syndrome.
  3. Uncontrolled hypertension, systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) >100 mmHg.
  4. Subjects with active ; previously treated brain metastasis was allowed if it had been stable for 4 weeks or more and had not required .
  5. Presence of .
  6. History of hemorrhagic diarrhea, inflammatory bowel disease, active uncontrolled peptic ulcer disease, recurrent pleural effusion requiring repetitive palliative thoracentesis within 3 months prior to study entry (except for subjects with a pleurex port), or immune mediated toxicity leading to treatment discontinuation.
  7. Active, known, or suspected serious disease, except for type I diabetes mellitus, hypothyroidism only requiring hormone replacement, and skin disorders (such as vitiligo, psoriasis, or alopecia).
  8. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
  9. Known history of testing positive for (HIV), known acquired immunodeficiency syndrome (AIDS).
  10. Active (serum hepatitis B surface antigen [HBsAg] positive) or (hepatitis C virus [HCV] antibody test or serum HCV RNA positive) indicating acute or chronic infection.
  11. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids were permitted.
  12. Use of other agents (drugs not marketed for any indication) within 28 days or at least 5 half lives (whichever is shorter) before study drug administration.
  13. Pregnant or breast feeding women.
  14. Second unless in remission for 2 years, except for non melanomatous skin cancer, carcinoma in situ of the cervix treated with curative intent, or curatively treated prostate cancer with prostate specific antigen (PSA) \<0.1 ng/mL.
  15. Underlying medical conditions that, in the Investigator's opinion, made the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.
  16. Unwilling or unable to comply with procedures required in this protocol.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    HBI-8000 in combination with nivolumab

    HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.

    Drug: HBI-8000 in combination with nivolumab

Interventions

  • DrugHBI-8000 in combination with nivolumab

    Drug pages: Tucidinostat · Nivolumab

    Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks. Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice.

    Also known as: For HBI-8000: Chidamide, CS055; for nivolumab: OPDIVO

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Experienced at Least One DLT During the DLT Assessment Period for MTD Determination

    The dose escalation schema of HBI 8000 followed the conventional 3+3 design. The starting dose was HBI 8000 20 mg twice a week. Dose escalation to 30 mg or 40 mg was determined by observation of DLT. At each dose level, a minimum of 3 subjects evaluable for DLT were enrolled. If 0 of the initial 3, or no more than 1 in a total 6 subjects experienced DLT, escalation to the next higher dose was allowed.

    Time frame: First 28 days

Secondary outcomes

  1. Objective Response Rate (ORR) in All Patients Treated at RP2D

    Percentage of patients with complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

    Time frame: From screening for baseline assessment to the date of CR or PR assessed, up to approximately 4 years and 7 months

  2. Disease Control Rate (DCR) in All Patients Treated at RP2D

    Percentage of patients with complete response (CR), partial response (PR) or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

    Time frame: From screening for baseline assessment to the date of best response (CR, PR, or SD) on study, up to approximately 4 years and 7 months

  3. Duration of Response (DoR) in All Patients Treated at RP2D

    Time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death.

    Time frame: From the date of CR or PR until the date of PD, or until the date of death, up to approximately 4 years and 7 months

  4. Progression-Free Survival (PFS) in All Patients Treated at RP2D

    Time from the date of first dose of HBI-8000 until tumor progression by site reported RECIST 1.1, or clinical progression, or death, whichever occurs first. If tumor progression data include more than 1 date of progression, the earliest date will be used.

    Time frame: From the date of first dose of HBI-8000 until tumor progression by site reported RECIST 1.1, or clinical progression, or death, whichever occurs first, up to approximately 4 years and 7 months

  5. Pharmacokinetic - Cmax (Single Dosing)

    Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

    Time frame: From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1, at 24 hours on Cycle 1 Day 2 (no dose administered)

  6. Pharmacokinetic - Cmax (Repeat Dosing)

    Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

    Time frame: From predose to 7 hours postdose on Cycle 2 Day 1

  7. Pharmacokinetic - AUC(0-7) (Single Dosing)

    Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.

    Time frame: From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1

  8. Pharmacokinetic - AUC(0-7) (Repeat Dosing)

    Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.

    Time frame: From predose to 7 hours postdose on Cycle 2 Day 1

  9. Pharmacokinetic - AUC(0-24)

    Area under the plasma concentration time curve from zero (predose) to 24 hours postdose, calculated by linear up/log down trapezoidal summation. Calculated for C1D1 only.

    Time frame: From predose (0.5 hour prior to breakfast) on Cycle 1 Day 1 to 24 hours on Cycle 1 Day 2 (no dose administered)

  10. Pharmacokinetic - Tmax (Single Dosing)

    Time of Cmax, obtained directly from the observed concentration versus time data.

    Time frame: From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1, at 24 hours on Cycle 1 Day 2 (no dose administered)

  11. Pharmacokinetic - Tmax (Repeat Dosing)

    Time of Cmax, obtained directly from the observed concentration versus time data.

    Time frame: From predose to 24 hours postdose on Cycle 2 Day 1

  12. QTcF Values >450 Msec

    Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.

    Time frame: 0 (predose) up to 4 hours postdose on C1D1 and C2D1

  13. QTcF Increase > 30 Msec

    Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.

    Time frame: 0 (predose) up to 4 hours postdose on C1D1 and C2D1

  14. Concentration Slope

    Slope estimate between ΔQTcF and HBI 8000 concentrations

    Time frame: 0 (predose) up to 4 hours postdose on C1D1 and C2D1

07

Results

Posted Jul 30, 2026

Participant flow

The first subject enrolled 18 August 2016 and the last subject enrolled 19 January 2021. All sites were located in the US.

Participant flow — Overall Study
MilestonePhase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With Nivolumab
Started37779
Completed0002
Not completed37777
Withdrew: Withdrawal by subject0105
Withdrew: Death24728
Withdrew: Lost to follow-up0004
Withdrew: Other - majority: completion of survival follow-up12040

Outcome measures

PrimaryNumber of Patients Who Experienced at Least One DLT During the DLT Assessment Period for MTD Determination

The dose escalation schema of HBI 8000 followed the conventional 3+3 design. The starting dose was HBI 8000 20 mg twice a week. Dose escalation to 30 mg or 40 mg was determined by observation of DLT. At each dose level, a minimum of 3 subjects evaluable for DLT were enrolled. If 0 of the initial 3, or no more than 1 in a total 6 subjects experienced DLT, escalation to the next higher dose was allowed.

Time frame:
First 28 days
Reported as:
Number · patients
Number of Patients Who Experienced at Least One DLT During the DLT Assessment Period for MTD Determination
patientsPhase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With Nivolumab
Number of Patients Who Experienced at Least One DLT During the DLT Assessment Period for MTD Determination002
SecondaryObjective Response Rate (ORR) in All Patients Treated at RP2D

Percentage of patients with complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

Time frame:
From screening for baseline assessment to the date of CR or PR assessed, up to approximately 4 years and 7 months
Reported as:
Number · Percentage of patients
Objective Response Rate (ORR) in All Patients Treated at RP2D
Percentage of patientsPhase 1b and 2 HBI-8000 30 mg: MelanomaPhase 1b and 2 HBI-8000 30 mg: NSCLCPhase 1b and 2 HBI-8000 30 mg: RCCPhase 1b and 2 HBI-8000 30 mg: Total
Objective Response Rate (ORR) in All Patients Treated at RP2D56.6 (42.3 to 70.2)22.7 (7.8 to 45.4)16.7 (0.4 to 64.1)44.4 (33.4 to 55.9)
SecondaryDisease Control Rate (DCR) in All Patients Treated at RP2D

Percentage of patients with complete response (CR), partial response (PR) or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

Time frame:
From screening for baseline assessment to the date of best response (CR, PR, or SD) on study, up to approximately 4 years and 7 months
Reported as:
Number · Percentage of patients
Disease Control Rate (DCR) in All Patients Treated at RP2D
Percentage of patientsPhase 1b and 2 HBI-8000 30 mg: MelanomaPhase 1b and 2 HBI-8000 30 mg: NSCLCPhase 1b and 2 HBI-8000 30 mg: RCCPhase 1b and 2 HBI-8000 30 mg: Total
Disease Control Rate (DCR) in All Patients Treated at RP2D84.9 (72.4 to 93.3)68.2 (45.1 to 86.1)66.7 (22.3 to 95.7)79.0 (68.5 to 87.3)
SecondaryDuration of Response (DoR) in All Patients Treated at RP2D

Time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death.

Time frame:
From the date of CR or PR until the date of PD, or until the date of death, up to approximately 4 years and 7 months
Reported as:
Median · Weeks
Duration of Response (DoR) in All Patients Treated at RP2D
WeeksPhase 1b and 2 HBI-8000 30 mg: MelanomaPhase 1b and 2 HBI-8000 30 mg: NSCLCPhase 1b and 2 HBI-8000 30 mg: RCCPhase 1b and 2 HBI-8000 30 mg: Total
Duration of Response (DoR) in All Patients Treated at RP2DNA (NA to NA)32.0 (15.9 to NA)89.4 (NA to NA)NA (81.1 to NA)
SecondaryProgression-Free Survival (PFS) in All Patients Treated at RP2D

Time from the date of first dose of HBI-8000 until tumor progression by site reported RECIST 1.1, or clinical progression, or death, whichever occurs first. If tumor progression data include more than 1 date of progression, the earliest date will be used.

Time frame:
From the date of first dose of HBI-8000 until tumor progression by site reported RECIST 1.1, or clinical progression, or death, whichever occurs first, up to approximately 4 years and 7 months
Reported as:
Median · Weeks
Progression-Free Survival (PFS) in All Patients Treated at RP2D
WeeksPhase 1b and 2 HBI-8000 30 mg: MelanomaPhase 1b and 2 HBI-8000 30 mg: NSCLCPhase 1b and 2 HBI-8000 30 mg: RCCPhase 1b and 2 HBI-8000 30 mg: Total
Progression-Free Survival (PFS) in All Patients Treated at RP2D79.6 (24.9 to NA)10.1 (7.6 to 55.7)14.6 (7.6 to NA)34.7 (22.1 to 70.4)
SecondaryPharmacokinetic - Cmax (Single Dosing)

Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

Time frame:
From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1, at 24 hours on Cycle 1 Day 2 (no dose administered)
Reported as:
Geometric mean · ng/mL
Pharmacokinetic - Cmax (Single Dosing)
ng/mLPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With NivolumabPhase 2/HBI-8000 30mg in Combination With Nivolumab
Pharmacokinetic - Cmax (Single Dosing)104.9 ± 32.2117.6 ± 34.0259.3 ± 73.5111.1 ± 52.2
SecondaryPharmacokinetic - Cmax (Repeat Dosing)

Maximum observed plasma concentration, obtained directly from the observed concentration versus time data.

Time frame:
From predose to 7 hours postdose on Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Pharmacokinetic - Cmax (Repeat Dosing)
ng/mLPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With NivolumabPhase 2/HBI-8000 30mg in Combination With Nivolumab
Pharmacokinetic - Cmax (Repeat Dosing)NA ± NA112.8 ± 93.8228.6 ± 72.996.79 ± 55.9
SecondaryPharmacokinetic - AUC(0-7) (Single Dosing)

Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.

Time frame:
From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetic - AUC(0-7) (Single Dosing)
ng*h/mLPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With NivolumabPhase 2/HBI-8000 30mg in Combination With Nivolumab
Pharmacokinetic - AUC(0-7) (Single Dosing)383.6 ± 8.9341.5 ± 97.8972.5 ± 124.2402.1 ± 94.3
SecondaryPharmacokinetic - AUC(0-7) (Repeat Dosing)

Area under the plasma concentration time curve from zero (predose) to 7 hours postdose, calculated by linear up/log down trapezoidal summation.

Time frame:
From predose to 7 hours postdose on Cycle 2 Day 1
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetic - AUC(0-7) (Repeat Dosing)
ng*h/mLPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With NivolumabPhase 2/HBI-8000 30mg in Combination With Nivolumab
Pharmacokinetic - AUC(0-7) (Repeat Dosing)NA ± NA392.2 ± 117.3929.4 ± 89.0433.0 ± 78.3
SecondaryPharmacokinetic - AUC(0-24)

Area under the plasma concentration time curve from zero (predose) to 24 hours postdose, calculated by linear up/log down trapezoidal summation. Calculated for C1D1 only.

Time frame:
From predose (0.5 hour prior to breakfast) on Cycle 1 Day 1 to 24 hours on Cycle 1 Day 2 (no dose administered)
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetic - AUC(0-24)
ng*h/mLPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With NivolumabPhase 2/HBI-8000 30mg in Combination With Nivolumab
Pharmacokinetic - AUC(0-24)1590 ± 29.71734 ± 29.33690 ± 54.91605 ± 44.5
SecondaryPharmacokinetic - Tmax (Single Dosing)

Time of Cmax, obtained directly from the observed concentration versus time data.

Time frame:
From predose (0.5 hour prior to breakfast) to 7 hours postdose on Cycle 1 Day 1, at 24 hours on Cycle 1 Day 2 (no dose administered)
Reported as:
Mean · h
Pharmacokinetic - Tmax (Single Dosing)
hPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With NivolumabPhase 2/HBI-8000 30mg in Combination With Nivolumab
Pharmacokinetic - Tmax (Single Dosing)6.083 ± 0.939311.054 ± 9.42874.426 ± 1.96826.715 ± 6.5280
SecondaryPharmacokinetic - Tmax (Repeat Dosing)

Time of Cmax, obtained directly from the observed concentration versus time data.

Time frame:
From predose to 24 hours postdose on Cycle 2 Day 1
Reported as:
Mean · h
Pharmacokinetic - Tmax (Repeat Dosing)
hPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With NivolumabPhase 2/HBI-8000 30mg in Combination With Nivolumab
Pharmacokinetic - Tmax (Repeat Dosing)NA ± NA5.833 ± 1.51905.613 ± 2.38976.693 ± 0.3244
SecondaryQTcF Values >450 Msec

Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.

Time frame:
0 (predose) up to 4 hours postdose on C1D1 and C2D1
Reported as:
Number · participants
QTcF Values >450 Msec
participantsPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With Nivolumab
QTcF Values >450 Msec000
SecondaryQTcF Increase > 30 Msec

Utilized a random coefficients mixed effects model for the change from baseline (ΔQTcF) values with continuous effects for HBI 8000 plasma concentration and baseline value (corrected for overall baseline mean), plus subject level random effects for intercept and concentration slope under unstructured covariance.

Time frame:
0 (predose) up to 4 hours postdose on C1D1 and C2D1
Reported as:
Number · participants
QTcF Increase > 30 Msec
participantsPhase 1/HBI-8000 20mg in Combination With NivolumabPhase 1/HBI-8000 30mg in Combination With NivolumabPhase 1/HBI-8000 40mg in Combination With Nivolumab
QTcF Increase > 30 Msec000
SecondaryConcentration Slope

Slope estimate between ΔQTcF and HBI 8000 concentrations

Time frame:
0 (predose) up to 4 hours postdose on C1D1 and C2D1
Reported as:
Number · ms/mg/ml
Concentration Slope
ms/mg/mlHBI-8000 in Combination With Nivolumab Phase 1b
Concentration Slope-0.02154 (-0.03426 to -0.008814)

Adverse events

Collected over From the first dose of study treatment until end of safety follow-up, up to 5 years 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: HBI-8000 20 mg in Combination With Nivolumab2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Phase 1b: HBI-8000 30 mg in Combination With Nivolumab4/7 (57.1%)6/7 (85.7%)7/7 (100%)
Phase 1b: HBI-8000 40 mg in Combination With Nivolumab7/7 (100%)4/7 (57.1%)7/7 (100%)
Phase 2: HBI-8000 30 mg in Combination With Nivolumab28/79 (35.4%)39/79 (49.4%)79/79 (100%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPhase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With Nivolumab
ColitisGastrointestinal disorders1/30/71/70/79
Systemic inflammatory response syndromeGeneral disorders1/30/70/70/79
PneumoniaInfections and infestations1/31/70/74/79
SomnolenceNervous system disorders1/30/70/70/79
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/30/71/73/79
Pleural effusionRespiratory, thoracic and mediastinal disorders0/32/70/72/79
AnaemiaBlood and lymphatic system disorders0/31/70/72/79
Angina pectorisCardiac disorders0/31/70/70/79
Atrial fibrillationCardiac disorders0/31/71/70/79
Cardiac arrestCardiac disorders0/30/71/71/79
Most frequent other events
Showing 10 of 200
Most frequent other events
EventPhase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With Nivolumab
FatigueGeneral disorders2/35/73/752/79
Weight decreasedInvestigations1/35/71/728/79
DiarrhoeaGastrointestinal disorders2/33/72/742/79
NauseaGastrointestinal disorders2/33/73/744/79
MyalgiaMusculoskeletal and connective tissue disorders2/30/71/711/79
DyspnoeaRespiratory, thoracic and mediastinal disorders2/34/73/731/79
AnaemiaBlood and lymphatic system disorders0/34/74/737/79
Oedema peripheralGeneral disorders1/34/72/729/79
Lipase increasedInvestigations0/34/71/719/79
Platelet count decreasedInvestigations0/34/73/742/79

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With NivolumabTotal
<=18 years00000
Between 18 and 65 years1314045
>=65 years2463951
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With NivolumabTotal
Female1133540
Male2644456
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With NivolumabTotal
Hispanic or Latino01056
Not Hispanic or Latino3677389
Unknown or Not Reported00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With NivolumabTotal
American Indian or Alaska Native00011
Asian00000
Black or African American00022
White3777390
Other00022
Not reported00011
Region of Enrollment
Region of Enrollment(participants)Phase 1b: HBI-8000 20 mg in Combination With NivolumabPhase 1b: HBI-8000 30 mg in Combination With NivolumabPhase 1b: HBI-8000 40 mg in Combination With NivolumabPhase 2: HBI-8000 30 mg in Combination With NivolumabTotal
United States3777996
08

Study locations

6 sites
  • [Site 02] Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • [Site 11] University of California, San Diego Medical Center
    La Jolla, California 92037, United States
  • [Site 01] Hematology - Oncology Associates of the Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Tampa, Florida 33612, United States
  • [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute
    Frederick, Maryland 21702, United States
  • [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Dec 2023, 87 months.

Results were first posted in Jul 2026, 2 years 7 months after primary completion.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 87 months is above that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2016
First posted
Mar 24, 2016
StartActual
Aug 18, 2016
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Results first posted
Jul 30, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02718066
Lead sponsor
HUYABIO International, LLC.
Responsible party
Sponsor
First posted
Mar 24, 2016
Start date
Aug 18, 2016
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Results posted
Jul 30, 2026
Last update
Jul 30, 2026

Study contacts

Nikhil I Khushalani, MD
principal investigator · H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Nivolumab

Start the discussion